You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDantrolene
Accession NumberDB01219  (APRD00901)
TypeSmall Molecule
GroupsApproved
DescriptionChemically, dantrolene is a hydantoin derivative, but does not exhibit antiepileptic activity like other hydantoin derivates such as phenytoin.
Structure
Thumb
Synonyms
Dantamacrin
Dantrium
Dantrolene
Dantroleno
Dantrolenum
F-368
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DantriumInjection20 mg/60mLIntravenousPar Pharmaceutical, Inc.2008-08-01Not applicableUs
DantriumCapsule25 mg/1OralPar Pharmaceutical Inc.2008-08-01Not applicableUs
DantriumCapsule50 mg/1OralPar Pharmaceutical Inc.2008-08-01Not applicableUs
DantriumCapsule100 mg/1OralPar Pharmaceutical Inc.2008-08-01Not applicableUs
Dantrium Cap 100mgCapsule100 mgOralNorwich Eaton Canada Inc.1979-12-311996-09-16Canada
Dantrium Cap 25mgCapsule25 mgOralNorwich Eaton Canada Inc.1979-12-311996-09-16Canada
Dantrium CapsulesCapsule100 mgOralPar Pharmaceutical Companies1993-12-31Not applicableCanada
Dantrium CapsulesCapsule25 mgOralPar Pharmaceutical Companies1993-12-31Not applicableCanada
Dantrium IntravenousPowder, for solution20 mgIntravenousPar Pharmaceutical Companies1993-12-31Not applicableCanada
Dantrolene SodiumCapsule25 mg/1OralPar Pharmaceutical Inc.2016-02-19Not applicableUs
Dantrolene SodiumCapsule25 mg/1OralJHP Pharmaceuticals, LLC2013-04-08Not applicableUs
Dantrolene SodiumCapsule50 mg/1OralPar Pharmaceutical Inc.2016-02-19Not applicableUs
Dantrolene SodiumCapsule50 mg/1OralJHP Pharmaceuticals, LLC2013-04-08Not applicableUs
Dantrolene SodiumCapsule100 mg/1OralPar Pharmaceutical Inc.2016-02-19Not applicableUs
Ryanodex Dantrolene SodiumInjection, suspension250 mg/5mLIntravenousEagle Pharmaceuticals, Inc.2014-07-23Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dantrolene SodiumCapsule25 mg/1OralImpax Generics2005-03-01Not applicableUs
Dantrolene SodiumCapsule25 mg/1OralAmerican Health Packaging2008-09-25Not applicableUs
Dantrolene SodiumCapsule50 mg/1OralImpax Generics2005-03-01Not applicableUs
Dantrolene SodiumCapsule25 mg/1OralCarilion Materials Management2005-03-01Not applicableUs
Dantrolene SodiumCapsule100 mg/1OralImpax Generics2005-03-01Not applicableUs
Dantrolene SodiumCapsule25 mg/1OralCardinal Health2008-09-25Not applicableUs
RevontoInjection, powder, lyophilized, for solution20 mg/60mLIntravenousUs World Meds, Llc2012-06-04Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DantamacrinSpepharm
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Dantrolene Sodium
Thumb
  • InChI Key: OZOMQRBLCMDCEG-VIZOYTHASA-N
  • Monoisotopic Mass: 314.06511945
  • Average Mass: 314.253
DBSALT000397
Categories
UNIIF64QU97QCR
CAS number7261-97-4
WeightAverage: 314.253
Monoisotopic: 314.06511945
Chemical FormulaC14H10N4O5
InChI KeyOZOMQRBLCMDCEG-VIZOYTHASA-N
InChI
InChI=1S/C14H10N4O5/c19-13-8-17(14(20)16-13)15-7-11-5-6-12(23-11)9-1-3-10(4-2-9)18(21)22/h1-7H,8H2,(H,16,19,20)/b15-7+
IUPAC Name
1-({[5-(4-nitrophenyl)furan-2-yl]methylidene}amino)imidazolidine-2,4-dione
SMILES
[O-][N+](=O)C1=CC=C(C=C1)C1=CC=C(O1)C=NN1CC(=O)NC1=O
Pharmacology
IndicationFor use, along with appropriate supportive measures, for the management of the fulminant hypermetabolism of skeletal muscle characteristic of malignant hyperthermia crises in patients of all ages. Also used preoperatively, and sometimes postoperatively, to prevent or attenuate the development of clinical and laboratory signs of malignant hyperthermia in individuals judged to be malignant hyperthermia susceptible.
Structured Indications
PharmacodynamicsDantrolene is classified as a direct-acting skeletal muscle relaxant. It is currently the only specific and effective treatment for malignant hyperthermia. In isolated nerve-muscle preparation, Dantrium has been shown to produce relaxation by affecting the contractile response of the muscle at a site beyond the myoneural junction. In skeletal muscle, Dantrium dissociates excitation-contraction coupling, probably by interfering with the release of Ca2+ from the sarcoplasmic reticulum. In the anesthetic-induced malignant hyperthermia syndrome, evidence points to an intrinsic abnormality of skeletal muscle tissue. In selected humans, it has been postulated that “triggering agents” (e.g.,general anesthetics and depolarizing neuromuscular blocking agents) produce a change within the cell which results in an elevated myoplasmic calcium. This elevated myoplasmic calcium activates acute cellular catabolic processes that cascade to the malignant hyperthermia crisis. It is hypothesized that addition of Dantrium to the “triggered” malignant hyperthermic muscle cell reestablishes a normal level of ionized calcium in the myoplasm.
Mechanism of actionDantrolene depresses excitation-contraction coupling in skeletal muscle by binding to the ryanodine receptor 1, and decreasing intracellular calcium concentration. Ryanodine receptors mediate the release of calcium from the sarcoplasmic reticulum, an essential step in muscle contraction.
TargetKindPharmacological actionActionsOrganismUniProt ID
Ryanodine receptor 1Proteinyes
antagonist
HumanP21817 details
Related Articles
AbsorptionBioavailability is 70%.
Volume of distributionNot Available
Protein bindingSignificant, mostly to albumin.
Metabolism

Hepatic, most likely by hepatic microsomal enzymes. Its major metabolites in body fluids are 5-hydroxydantrolene and an acetylamino metabolite of dantrolene. Another metabolite with an unknown structure appears related to the latter. Dantrium may also undergo hydrolysis and subsequent oxidation forming nitrophenylfuroic acid.

SubstrateEnzymesProduct
Dantrolene
Not Available
5-hydroxydantroleneDetails
Route of eliminationNot Available
Half lifeThe mean biologic half-life after intravenous administration is variable, between 4 to 8 hours under most experimental conditions, while oral is 8.7 hours for a 100mg dose.
ClearanceNot Available
ToxicityOral LD50 in rats is 7400 mg/kg. Symptoms which may occur in case of overdose include, but are not limited to, muscular weakness and alterations in the state of consciousness (e.g., lethargy, coma), vomiting, diarrhea, and crystalluria.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Dantrolene is combined with 1,1,1,2 Tetrafluoroethane.Investigational
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Dantrolene.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Dantrolene.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Dantrolene.Approved
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Dantrolene.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Dantrolene.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Dantrolene.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Dantrolene.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Dantrolene.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Dantrolene.Approved, Illicit, Investigational
AmiodaroneThe metabolism of Dantrolene can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Dantrolene.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Dantrolene.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Dantrolene.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Dantrolene.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Dantrolene.Experimental
AprepitantThe serum concentration of Dantrolene can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Dantrolene.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Dantrolene.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Dantrolene.Approved
AtazanavirThe metabolism of Dantrolene can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Dantrolene can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Dantrolene.Vet Approved
AzelastineDantrolene may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Dantrolene.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Dantrolene.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Dantrolene.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Dantrolene is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Dantrolene.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Dantrolene.Approved
BexaroteneThe serum concentration of Dantrolene can be decreased when it is combined with Bexarotene.Approved, Investigational
BoceprevirThe metabolism of Dantrolene can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Dantrolene can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Dantrolene can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Dantrolene is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Dantrolene.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Dantrolene.Approved, Illicit
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Dantrolene.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Dantrolene.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Dantrolene.Approved, Investigational
BuprenorphineDantrolene may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Dantrolene.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Dantrolene.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Dantrolene.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Dantrolene.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Dantrolene.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Dantrolene.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Dantrolene.Approved, Illicit, Vet Approved
CarbamazepineThe metabolism of Dantrolene can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Dantrolene.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Dantrolene.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Dantrolene.Approved
CeritinibThe serum concentration of Dantrolene can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Dantrolene.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Dantrolene.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Dantrolene.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Dantrolene.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Dantrolene.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Dantrolene.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Dantrolene.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Dantrolene.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Dantrolene.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Dantrolene.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Dantrolene is combined with Citalopram.Approved
ClarithromycinThe metabolism of Dantrolene can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Dantrolene can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Dantrolene.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Dantrolene.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Dantrolene.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Dantrolene.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Dantrolene.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Dantrolene.Approved, Illicit
ClotrimazoleThe metabolism of Dantrolene can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Dantrolene.Approved
CobicistatThe metabolism of Dantrolene can be decreased when combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Dantrolene.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Dantrolene.Approved, Illicit
ConivaptanThe serum concentration of Dantrolene can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Dantrolene can be decreased when combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Dantrolene.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dantrolene.Approved
CyclosporineThe metabolism of Dantrolene can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Dantrolene.Approved
DabrafenibThe serum concentration of Dantrolene can be decreased when it is combined with Dabrafenib.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Dantrolene.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Dapoxetine.Investigational
DarunavirThe metabolism of Dantrolene can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Dantrolene can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Dantrolene can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Dantrolene can be decreased when combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Dantrolene.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Dantrolene.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Dantrolene.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Dantrolene.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Dantrolene.Vet Approved
DexamethasoneThe serum concentration of Dantrolene can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Dantrolene.Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Dantrolene.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dantrolene.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Dantrolene.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Dantrolene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Dantrolene.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Dantrolene.Approved, Illicit, Vet Approved
DifenoxinThe risk or severity of adverse effects can be increased when Dantrolene is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Dantrolene.Approved, Illicit
DihydroergotamineThe metabolism of Dantrolene can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Dantrolene.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Dantrolene.Experimental, Illicit
DiltiazemDantrolene may increase the hyperkalemic activities of Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Dantrolene.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Dantrolene.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Dantrolene.Approved, Illicit
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Dantrolene.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Dantrolene.Approved
DoxycyclineThe metabolism of Dantrolene can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Dantrolene.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.Approved, Illicit
DronedaroneThe metabolism of Dantrolene can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Dantrolene.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Dantrolene.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Dantrolene.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Dantrolene.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Dantrolene is combined with Ecopipam.Investigational
EfavirenzThe serum concentration of Dantrolene can be decreased when it is combined with Efavirenz.Approved, Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Dantrolene.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Dantrolene.Approved, Investigational
EnzalutamideThe serum concentration of Dantrolene can be decreased when it is combined with Enzalutamide.Approved
ErythromycinThe metabolism of Dantrolene can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Dantrolene is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Dantrolene can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Dantrolene.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Dantrolene.Approved
EthanolDantrolene may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Dantrolene.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Dantrolene.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Dantrolene.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Dantrolene.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Dantrolene.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Dantrolene.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Dantrolene.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Dantrolene.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Dantrolene.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Dantrolene.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Dantrolene.Illicit, Vet Approved
EtravirineThe serum concentration of Dantrolene can be decreased when it is combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Dantrolene.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Dantrolene.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Dantrolene.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Dantrolene.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Dantrolene is combined with Flibanserin.Approved
FluconazoleThe metabolism of Dantrolene can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Dantrolene.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Dantrolene.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Dantrolene.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Dantrolene.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Dantrolene.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Dantrolene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Dantrolene.Approved
FluvoxamineThe metabolism of Dantrolene can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Dantrolene can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Dantrolene can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Dantrolene can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Dantrolene.Approved, Illicit
Fusidic AcidThe serum concentration of Dantrolene can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Dantrolene.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Dantrolene is combined with gabapentin enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Dantrolene.Approved, Illicit
GepironeThe risk or severity of adverse effects can be increased when Dantrolene is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Dantrolene.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Dantrolene.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Dantrolene.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Dantrolene.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Dantrolene.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Dantrolene.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Dantrolene.Approved
HydrocodoneDantrolene may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Dantrolene.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.Approved
IdelalisibThe serum concentration of Dantrolene can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Iloperidone.Approved
ImatinibThe metabolism of Dantrolene can be decreased when combined with Imatinib.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Dantrolene.Approved
IndalpineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Indalpine.Investigational, Withdrawn
IndinavirThe metabolism of Dantrolene can be decreased when combined with Indinavir.Approved
IsavuconazoniumThe metabolism of Dantrolene can be decreased when combined with Isavuconazonium.Approved, Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Dantrolene.Approved, Vet Approved
IsradipineThe metabolism of Dantrolene can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Dantrolene can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Dantrolene can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Dantrolene.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Dantrolene.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Dantrolene.Approved
KetoconazoleThe metabolism of Dantrolene can be decreased when combined with Ketoconazole.Approved, Investigational
LacidipineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Dantrolene.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Dantrolene.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Dantrolene.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Dantrolene.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Dantrolene is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Dantrolene.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Dantrolene is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Dantrolene.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Dantrolene.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Dantrolene.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Dantrolene.Illicit
LopinavirThe metabolism of Dantrolene can be decreased when combined with Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Dantrolene.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Dantrolene.Approved
LovastatinThe metabolism of Dantrolene can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Dantrolene.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Dantrolene.Investigational
LuliconazoleThe serum concentration of Dantrolene can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Dantrolene can be increased when combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Dantrolene.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Dantrolene.Approved
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Dantrolene.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Dantrolene.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Dantrolene.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Dantrolene.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Dantrolene.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dantrolene.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Dantrolene.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Dantrolene.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Dantrolene.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Dantrolene.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Dantrolene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Dantrolene.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Dantrolene.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Dantrolene.Approved
MethotrimeprazineDantrolene may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Dantrolene.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Dantrolene is combined with Methsuximide.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Dantrolene.Approved
MetyrosineDantrolene may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Dantrolene.Approved, Illicit
MifepristoneThe serum concentration of Dantrolene can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Dantrolene is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.Approved, Investigational
MirtazapineDantrolene may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Dantrolene can be decreased when it is combined with Mitotane.Approved
ModafinilThe serum concentration of Dantrolene can be decreased when it is combined with Modafinil.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Dantrolene.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Dantrolene.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.Approved, Investigational
NafcillinThe serum concentration of Dantrolene can be decreased when it is combined with Nafcillin.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Dantrolene.Approved
NefazodoneThe metabolism of Dantrolene can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Dantrolene can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Dantrolene can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Dantrolene can be increased when combined with Nevirapine.Approved
NilotinibThe metabolism of Dantrolene can be decreased when combined with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Dantrolene.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Dantrolene.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Dantrolene.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Dantrolene.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Dantrolene.Approved, Investigational
OlaparibThe metabolism of Dantrolene can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Dantrolene.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Dantrolene.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Dantrolene.Approved, Illicit
OrphenadrineDantrolene may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Dantrolene.Investigational
OsimertinibThe serum concentration of Dantrolene can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Dantrolene.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Dantrolene.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Dantrolene.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Dantrolene.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Dantrolene.Approved, Investigational, Vet Approved
PalbociclibThe serum concentration of Dantrolene can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Dantrolene.Approved
ParaldehydeDantrolene may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Paroxetine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Dantrolene.Approved, Vet Approved
PentobarbitalThe metabolism of Dantrolene can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.Approved
PerazineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Dantrolene.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Dantrolene.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Dantrolene.Approved
PhenobarbitalThe metabolism of Dantrolene can be increased when combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Dantrolene.Approved
PhenytoinThe metabolism of Dantrolene can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Dantrolene.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Dantrolene.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Dantrolene is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Dantrolene is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Dantrolene is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Dantrolene can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleDantrolene may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Dantrolene.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Dantrolene.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Dantrolene.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Dantrolene.Approved
PrimidoneThe metabolism of Dantrolene can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Dantrolene.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dantrolene.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Dantrolene.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Dantrolene.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Dantrolene.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Dantrolene.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Dantrolene.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Dantrolene.Approved
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Dantrolene.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Dantrolene.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dantrolene.Approved
RacloprideThe risk or severity of adverse effects can be increased when Dantrolene is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Dantrolene.Approved, Investigational
RanolazineThe metabolism of Dantrolene can be decreased when combined with Ranolazine.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Dantrolene.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Dantrolene.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Dantrolene.Approved
RifabutinThe metabolism of Dantrolene can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Dantrolene can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Dantrolene can be increased when combined with Rifapentine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Dantrolene.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Dantrolene is combined with Ritanserin.Investigational
RitonavirThe metabolism of Dantrolene can be decreased when combined with Ritonavir.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Dantrolene.Vet Approved
RopiniroleDantrolene may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Dantrolene.Approved
RotigotineDantrolene may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Dantrolene.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Dantrolene.Experimental
Sage 547The risk or severity of adverse effects can be increased when Dantrolene is combined with Sage 547.Investigational
SaquinavirThe metabolism of Dantrolene can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dantrolene.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Dantrolene.Approved, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Dantrolene.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Dantrolene.Approved, Vet Approved
SildenafilThe metabolism of Dantrolene can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Dantrolene can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Dantrolene can be increased when it is combined with Simeprevir.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.Approved
St. John's WortThe serum concentration of Dantrolene can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Dantrolene can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Dantrolene.Approved, Investigational
SulfisoxazoleThe metabolism of Dantrolene can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Dantrolene.Approved
SuvorexantDantrolene may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Dantrolene is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Dantrolene is combined with Tasimelteon.Approved
TelaprevirThe metabolism of Dantrolene can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Dantrolene can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Dantrolene.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Dantrolene.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Dantrolene.Investigational
ThalidomideDantrolene may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Dantrolene.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Dantrolene.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Dantrolene.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Dantrolene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Dantrolene.Approved
TiaprideThe risk or severity of adverse effects can be increased when Dantrolene is combined with Tiapride.Investigational
TiclopidineThe metabolism of Dantrolene can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Dantrolene.Vet Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Dantrolene.Approved
TocilizumabThe serum concentration of Dantrolene can be decreased when it is combined with Tocilizumab.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Dantrolene.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Dantrolene.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Dantrolene.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Dantrolene.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Dantrolene.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Dantrolene.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Dantrolene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Dantrolene.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Dantrolene.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Dantrolene.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Dantrolene.Approved
Uc1010The risk or severity of adverse effects can be increased when Dantrolene is combined with Uc1010.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Dantrolene.Approved, Investigational
VecuroniumDantrolene may increase the neuromuscular blocking activities of Vecuronium.Approved
VenlafaxineThe metabolism of Dantrolene can be decreased when combined with Venlafaxine.Approved
VerapamilDantrolene may increase the hyperkalemic activities of Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Dantrolene.Approved
VoriconazoleThe metabolism of Dantrolene can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Dantrolene.Approved
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Dantrolene.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Dantrolene.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Dantrolene is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Dantrolene is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Dantrolene can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Dantrolene.Vet Approved
ZolpidemDantrolene may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Dantrolene.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Dantrolene.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Dantrolene.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Dantrolene.Approved, Investigational
Food Interactions
  • Take without regard to meals.
References
Synthesis Reference

Davis, C.S. and Snyder, H.R. Jr.; US. Patent 3,415,821; December 10, 1968; assigned to
The Norwich Pharmacal Company.

General References
  1. Krause T, Gerbershagen MU, Fiege M, Weisshorn R, Wappler F: Dantrolene--a review of its pharmacology, therapeutic use and new developments. Anaesthesia. 2004 Apr;59(4):364-73. [PubMed:15023108 ]
External Links
ATC CodesM03CA01
AHFS Codes
  • 12:20.00
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (43 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9974
Blood Brain Barrier+0.9581
Caco-2 permeable-0.5587
P-glycoprotein substrateNon-substrate0.6562
P-glycoprotein inhibitor INon-inhibitor0.8977
P-glycoprotein inhibitor IINon-inhibitor0.978
Renal organic cation transporterNon-inhibitor0.8656
CYP450 2C9 substrateNon-substrate0.81
CYP450 2D6 substrateNon-substrate0.8935
CYP450 3A4 substrateSubstrate0.5848
CYP450 1A2 substrateInhibitor0.8916
CYP450 2C9 inhibitorNon-inhibitor0.8808
CYP450 2D6 inhibitorNon-inhibitor0.9203
CYP450 2C19 inhibitorNon-inhibitor0.8752
CYP450 3A4 inhibitorNon-inhibitor0.8985
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7676
Ames testAMES toxic0.8925
CarcinogenicityNon-carcinogens0.8732
BiodegradationReady biodegradable0.5901
Rat acute toxicity2.5390 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7215
hERG inhibition (predictor II)Non-inhibitor0.9223
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
InjectionIntravenous20 mg/60mL
CapsuleOral100 mg
CapsuleOral25 mg
Powder, for solutionIntravenous20 mg
CapsuleOral100 mg/1
CapsuleOral25 mg/1
CapsuleOral50 mg/1
Injection, powder, lyophilized, for solutionIntravenous20 mg/60mL
Injection, suspensionIntravenous250 mg/5mL
Prices
Unit descriptionCostUnit
Dantrium 20 mg vial106.37USD vial
Dantrolene sodium 20 mg vial97.2USD vial
Dantrolene sodium powder17.6USD g
Dantrium 100 mg capsule2.4USD capsule
Dantrolene sodium 100 mg capsule2.03USD capsule
Dantrium 50 mg capsule1.93USD capsule
Dantrolene sodium 50 mg capsule1.63USD capsule
Dantrium 25 mg capsule1.29USD capsule
Dantrolene sodium 25 mg capsule1.09USD capsule
Dantrium 100 mg Capsule0.8USD capsule
Dantrium 25 mg Capsule0.4USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7758890 No2005-07-012025-07-01Us
US8110225 No2002-12-242022-12-24Us
US8604072 No2002-12-242022-12-24Us
US8685460 No2003-02-152023-02-15Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point279-280 °CDavis, C.S. and Snyder, H.R. Jr.; US. Patent 3,415,821; December 10, 1968; assigned to The Norwich Pharmacal Company.
water solubilityLow (146 mg/L)Not Available
logP1.70JANSEN,ACA ET AL. (1991)
Predicted Properties
PropertyValueSource
Water Solubility0.0805 mg/mLALOGPS
logP1.65ALOGPS
logP1.26ChemAxon
logS-3.6ALOGPS
pKa (Strongest Acidic)9.23ChemAxon
pKa (Strongest Basic)-1.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area120.73 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity78.87 m3·mol-1ChemAxon
Polarizability29.98 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as hydantoins. These are heterocyclic compounds containing an imidazolidine substituted by ketone group at positions 2 and 4.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassAzolidines
Sub ClassImidazolidines
Direct ParentHydantoins
Alternative Parents
Substituents
  • Hydantoin
  • Nitrobenzene
  • Ureide
  • Benzenoid
  • Semicarbazone
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Semicarbazide
  • Furan
  • Organic nitro compound
  • Organic nitrite
  • C-nitro compound
  • Carboxamide group
  • Oxacycle
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Allyl-type 1,3-dipolar organic compound
  • Organic oxoazanium
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organic salt
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Organic zwitterion
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Voltage-gated calcium channel activity
Specific Function:
Calcium channel that mediates the release of Ca(2+) from the sarcoplasmic reticulum into the cytoplasm and thereby plays a key role in triggering muscle contraction following depolarization of T-tubules. Repeated very high-level exercise increases the open probability of the channel and leads to Ca(2+) leaking into the cytoplasm. Can also mediate the release of Ca(2+) from intracellular stores ...
Gene Name:
RYR1
Uniprot ID:
P21817
Molecular Weight:
565170.715 Da
References
  1. Britt BA, Scott E, Frodis W, Clements MJ, Endrenyi L: Dantrolene--in vitro studies in malignant hyperthermia susceptible (MHS) and normal skeletal muscle. Can Anaesth Soc J. 1984 Mar;31(2):130-54. [PubMed:6704779 ]
  2. Harrison GG: Control of the malignant hyperpyrexic syndrome in MHS swine by dantrolene sodium. 1975. Br J Anaesth. 1998 Oct;81(4):626-9; discussion 625. [PubMed:9924249 ]
  3. Flewellen EH, Nelson TE: Dantrolene dose response in malignant hyperthermia-susceptible (MHS) swine: method to obtain prophylaxis and therapeusis. Anesthesiology. 1980 Apr;52(4):303-8. [PubMed:7362049 ]
  4. Tonner PH, Scholz J, Richter A, Loscher W, Steinfath M, Wappler F, Wlaz P, Hadji B, Roewer N, Schulte am Esch J: Alterations of inositol polyphosphates in skeletal muscle during porcine malignant hyperthermia. Br J Anaesth. 1995 Oct;75(4):467-71. [PubMed:7488490 ]
  5. Zhao X, Weisleder N, Han X, Pan Z, Parness J, Brotto M, Ma J: Azumolene inhibits a component of store-operated calcium entry coupled to the skeletal muscle ryanodine receptor. J Biol Chem. 2006 Nov 3;281(44):33477-86. Epub 2006 Aug 31. [PubMed:16945924 ]
  6. Krause T, Gerbershagen MU, Fiege M, Weisshorn R, Wappler F: Dantrolene--a review of its pharmacology, therapeutic use and new developments. Anaesthesia. 2004 Apr;59(4):364-73. [PubMed:15023108 ]
  7. Gerbershagen MU, Fiege M, Krause T, Agarwal K, Wappler F: [Dantrolene. Pharmacological and therapeutic aspects]. Anaesthesist. 2003 Mar;52(3):238-45. [PubMed:12666006 ]
  8. Paul-Pletzer K, Yamamoto T, Bhat MB, Ma J, Ikemoto N, Jimenez LS, Morimoto H, Williams PG, Parness J: Identification of a dantrolene-binding sequence on the skeletal muscle ryanodine receptor. J Biol Chem. 2002 Sep 20;277(38):34918-23. Epub 2002 Jul 11. [PubMed:12167662 ]
  9. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 02, 2016 02:44